The UK's NHS plans to keep its £330M Palantir contract until 2029, rather than triggering an early release clause in 2027; the deal was due to run until 2031 (Hugh Pym/BBC)
The National Health Service intends to retain its £330 million partnership with Palantir through 2029. Rather than enacting a contractual break clause set for 2027, the health service will extend its collaboration by an additional two years past that threshold. Although the original terms scheduled the deal to run through 2031, leadership is focusing on maintaining services until the revised 2029 target.
Key points
Choosing not to trigger the 2027 break clause guarantees at least two more years of partn…: Choosing not to trigger the 2027 break clause guarantees at least two more years of partnership.
The overarching agreement was originally drawn up with a timeline extending through 2031.: The overarching agreement was originally drawn up with a timeline extending through 2031.
Palantir will continue providing its data services to the UK health sector under the exte…: Palantir will continue providing its data services to the UK health sector under the extended plan.
Sources checked by our analysis pipeline: 1
Nvidia Newsroom: |
Kanishka Singh / Reuters: |
Kai Nicol-Schwarz / CNBC: |
Lingling Wei / Wall Street Journal: |
CNBC: |
New York Times: |
Wall Street Journal: |
Emily Goodin / New York Post: |
Scott Helme / Report URI Blog: |
Bloomberg: |
Juli Clover / MacRumors: |
Politico: |
Jeffrey Kampman / Tom's Hardware: |
Reuters: |
Mauro Orru / Wall Street Journal: |
Kif Leswing / CNBC: |
Nate Raymond / Reuters: |
Yazhou Sun / Bloomberg: |
Camila Grigera Naón / Fortune: |
Financial Times: |
Hugh Pym / BBC: |
Vicky Ge Huang / Wall Street Journal: |
Rafe Rosner-Uddin / Financial Times: |
Reuters: |
Natalie Lung / Bloomberg: |
Groundwork Collaborative: |
Gergely Orosz / The Pragmatic Engineer: |
This is a Techmeme archive page. It shows how the site appeared at 8:15 AM ET, November 17, 2026.
The most current version of the site as always is available at our home page. To view an earlier snapshot click here and then modify the date indicated.
Physician-scientist John Powers III has taken permanent leadership of the National Institute of Allergy and Infectious Diseases following the contentious departure of Jeanne Marrazzo in 2025. Having previously served as acting director since June, he favors redirecting research resources away from HIV and pandemic readiness toward wider immunology initiatives alongside the broader agency leadership.
Palestinian officials and the Israeli military have offered starkly conflicting accounts following a fatal confrontation linked to a newly established settler outpost in al-Duyuk al-Tahta. While local reports state Israeli settlers initiated gunfire outside a family residence, the Israel Defense Forces maintained that Israelis discharged weapons in self-defense following a deliberate vehicle ramming and physical assault. The deadly event coincides with mounting international scrutiny and fresh British economic pen…
British ministers declined an option to exit the £330m healthcare agreement next year, choosing instead to initiate a fresh procurement process next summer that invites domestic companies to bid for work beginning later in the decade. The decision seeks to prevent single-supplier dependence while keeping software deployed to address persistent hospital backlogs. However, the continuation faces intense political scrutiny regarding patient confidentiality and the American firm's outside defence ties.